Dexmedetomidine Versus Hyalase Treatment of Carpal Tunnel Syndrome
CompletedNot applicableNCT05280223
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent hydro-dissection hyalase and saline versus dexmedetomidine upon the median nerve could offer symptoms and clinical improvement
Study details
- Official title
- Dexmedetomidine Versus Hyalase Local Injection for Pain Alleviation in Patients With Carpal Tunnel Syndrome; A Randomized Clinical Trial
- Conditions
- Interventions
- Drug: Dexmedetomidine
- Drug: Hyalase
- Sponsor
- Assiut University
- Start date
- 2022-04-01
- Primary completion
- 2023-06-30
- Sex
- All
- Age range
- from 18 Years to 60 Years
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * adult patients * complaining of carpal tunnel syndrome of 3 month duration or more * diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study Exclusion Criteria: * • patient refusal infection at the site of intervention * local anesthetic allergy
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05280223